Hampshire, UK — 7 May 2024

TMC Pharma Services Ltd., an established global product development and clinical research organisation (CRO) headquartered in Hampshire UK, is pleased to announce the appointment of Simon Estcourt as its new CEO, effective 7 May 2024.

Simon joins from Abacus Medicine Pharma Services, where he was Managing Director, successfully growing the company by partnering with developers of innovative therapies and tailoring bespoke commercialisation solutions. He brings a wealth of senior leadership experience in the pharma services space and will support TMC with its continued global expansion.

Following an £18 million minority investment by LDC, the private equity investor which is part of Lloyds Banking Group, in August 2022, TMC has been on a mission to expand its established US and EU client base, to increase activities in AsiaPac and beyond and to strengthen its international team, including some strategically-valuable alliances and acquisitions. Simon’s appointment continues to strengthen the company’s leadership team.

Simon will spearhead the next exciting phase of TMC’s development - promising to harness his 25 years of strategic experience to take the company to new heights. Having worked in partnership with many pharma and biotech companies on programmes that have helped thousands of patients worldwide, he is uniquely qualified to step into this role.

Simon Estcourt commented,

‘On both a professional and personal level, I am really looking forward to guiding TMC through this period of growth. This is a great opportunity to continue to build this extraordinary company and I’m very excited to join such a well-regarded in-house team of experienced experts and specialist Associates. Together, we can maximise TMC’s countless strengths and make the most of emerging opportunities.’

This appointment is part of the company’s long-term succession plan and Simon succeeds Julie Matthews, who co-founded TMC with her physician husband, Dr Mike Matthews, in 2000, to provide drug development support to pharma/biotech companies; predominantly within rare, orphan and oncology diseases. Julie will continue as a non-executive director to support further expansion on the strong foundations that have successfully built TMC over the last 20+ years.

Julie commented, ‘I’m incredibly proud of what we have achieved at TMC over the past two decades, with our championing of the development of treatments for rare diseases. Simon shares our values and ambition and I have no doubt he will enable us to continue extending our reach by capitalising on our exceptional services that have already made a meaningful impact on so many patients’ lives. Under Simon’s leadership, TMC’s clients can expect the same superior standards of quality and execution – supported by new partnerships, new targets and fresh energy.’

Published On: 7 May 2024By Categories: News